Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®

Agile Therapeutics (NASDAQ:AGRX) has announced that the US Food and Drug Administration (FDA) has accepted for review its new drug...

Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Low-Dose Contraceptive Patch,

Agile Therapeutics (NASDAQ:AGRX) has announced it has resubmitted to the US Food and Drug Administration (FDA) its new drug application...

Agile Therapeutics Provides Regulatory Update and Reiterates Cash Guidance

Agile Therapeutics (Nasdaq:AGRX), a women’s healthcare company, announced that on January 9, 2019 it received final meeting minutes from its...